MSB 7.69% $1.19 mesoblast limited

Ann: CEO Presentation to 2023 Annual General Meeting, page-8

  1. 48 Posts.
    lightbulb Created with Sketch. 43
    One of the interesting things that SI indicated in the less formal chat afterwards was that working with Surgecentre and a large partner may both be possible ..he was alert to not dealing out a big partner whilst still keeping Surgecentre interested in the trial and/or possible later distribution /delivery through their clinics
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.